Your browser is old and is not supported. Upgrade for better security.

Invest in Hera Diagnostics

Hera Diagnostics saves lives by delivering cervical cancer screening to the global community

Pitch Video
Investor Panel

Highlights

1
Over 300,000 women die annually from cervical cancer even though the disease is easily treatable
2
90% of cervical cancer deaths occur in underserved populations globally
3
Hera will reduce those deaths by delivering high-tech screening to low-tech communities
4
Our device is portable, accurate, affordable, painless and gives real time, point-of-care results
5
Phase 1 begins 2021: Mexico then Chile, Peru, Colombia, Brazil, Argentina, Bolivia, China, India
6
Projected annual revenues exceed $100M in our phase 1 markets alone
7
Hygienic protective sleeves generate attractive recurring revenue streams for each deployed device
8
Team is composed of talented women, LatinX technologists and proven company builders.

Our Team

Cervical cancer is a leading cause of death from cancer among women in developing countries. Hera Diagnostics technology was developed to address this crisis through reliable, affordable and immediate screening technology.

Pitch

Overview